Accord Biopharma

NC - Raleigh

Pharmaceutical1 H-1B visas (FY2023)

Website LinkedIn Careers Page

Focus: Specialty Pharma, Biosimilars

Accord Biopharma is a life sciences company focused on Specialty Pharma, Biosimilars.

OncologyCardiovascularNeurologyImmunologyHematology

Funding Stage

PUBLIC

Open Jobs

Products & Portfolio (37)

13 discontinued products not shown

ACETAZOLAMIDE

acetazolamide

Post-LOE

ORAL · CAPSULE, EXTENDED RELEASE

Carbonic Anhydrase Inhibitors

Xanthine Oxidase Inhibitors

leukemialymphoma

2013

AMITRIPTYLINE HYDROCHLORIDE

amitriptyline hydrochloride

Post-LOE

ORAL · TABLET

CLINICAL PHARMACOLOGY Amitriptyline hydrochloride is an antidepressant with sedative effects. Its mechanism of action in man is not known. It is not a monoamine oxidase inhibitor and it does not act primarily by stimulation of the central nervous system. Amitriptyline inhibits the membrane pump mechanism responsible for uptake of norepinephrine and serotonin in adrenergic and serotonergic neurons. Pharmacologically, this action may potentiate or prolong neuronal activity since reuptake of these biogenic amines is important physiologically in terminating transmitting activity. This interference with reuptake of norepinephrine and/or serotonin is believed by some to underlie the antidepressant activity of amitriptyline.

(calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected in vitro but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by amlodipine. Within the physiologic pH range, amlodipine is an ionized compound (pKa=8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure. The precise mechanisms by which amlodipine relieves angina have not been fully delineated, but are thought to include the following: Exertional Angina: In patients with exertional angina, amlodipine reduces the total peripheral resistance (afterload) against which the heart works and reduces the rate pressure product, and thus myocardial oxygen demand, at any given level of exercise. Vasospastic Angina: Amlodipine has been demonstrated to block constriction and restore blood flow in coronary arteries and arterioles in response to calcium, potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal models and in human coronary vessels in vitro . This inhibition of coronary spasm is responsible for the effectiveness of amlodipine in vasospastic (Prinzmetal's or variant) angina.

hypertensionto lower blood pressureconfirmed+4 more

advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapybreast cancer

FXa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.

deep vein thrombosis (DVT)which may lead to pulmonary embolism (PE)knee replacement surgery+10 more

2020

ARGATROBAN IN SODIUM CHLORIDE

argatroban

Peak

INTRAVENOUS · SOLUTION

Thrombin Inhibitors

For prophylaxis or treatment of thrombosis

unclear. However, the efficacy of aripiprazole in the listed indications could be mediated through a combination of partial agonist activity at D 2 and 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.

selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. In animal models, atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces LDL production and the number of LDL particles.

type 2 diabetes mellitusheart failure

INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL · SOLUTION

muscarine-like actions of acetylcholine and other choline esters. Atropine inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves, and on smooth muscles which respond to endogenous acetylcholine but are not so innervated. As with other antimuscarinic agents, the major action of atropine is a competitive or surmountable antagonism which can be overcome by increasing the concentration of acetylcholine at receptor sites of the effector organ (e.g., by using anticholinesterase agents which inhibit the enzymatic destruction of acetylcholine). The receptors antagonized by atropine are the peripheral structures that are stimulated or inhibited by muscarine (i.e., exocrine glands and smooth and cardiac muscle). Responses to postganglionic cholinergic nerve stimulation also may be inhibited by atropine but this occurs less readily than with responses to injected (exogenous) choline esters.

INTRAVENOUS · SOLUTION

INTRAVENOUS, SUBCUTANEOUS · POWDER

Nucleic Acid Synthesis Inhibitors

refractory anemia with ringed sideroblasts (if accompanied by neutropeniathrombocytopeniarequiring transfusions)+5 more

2018

View all 37 products

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 168 approved products

Top TAs: Oncology, Cardiovascular, Neurology

H-1B (2023): 1 approval

Portfolio Health

Pre-Launch4 (2%)

Launch4 (2%)

Growth2 (1%)

Peak12 (7%)

Post-LOE146 (87%)

168 total products

Therapeutic Area Focus

32 marketed

20 marketed

12 marketed

5 marketed

5 marketed

4 marketed

4 marketed

4 marketed

Marketed

Pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub